1 SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness
2 Kizzmekia S. Corbett1#, Darin Edwards2#, Sarah R. Leist3#, Olubukola M. Abiona1
3 , SeyhanBoyoglu-Barnum1, Rebecca A. Gillespie1, Sunny Himansu2, Alexandra Schäfer3
4 , Cynthia T.Ziwawo1, Anthony T. DiPiazza1, Kenneth H. Dinnon3, Sayda M. Elbashir2, Christine A. Shaw2
5 ,Angela Woods2, Ethan J. Fritch4, David R.Martinez3, Kevin W. Bock5, Mahnaz Minai5
6 , BiancaM. Nagata5, Geoffrey B.Hutchinson1, Kapil Bahl2, Dario Garcia Dominguez2, LingZhi Ma2
7 ,Isabella Renzi2, Wing-Pui Kong1, Stephen D. Schmidt1, Lingshu Wang1, Yi Zhang1
8 , Laura J.Stevens6, Emily Phung7, Lauren A. Chang1, Rebecca J. Loomis1, Nedim Emil Altaras2
9 , Elisabeth Narayanan2, Mihir Metkar2, Vlad Presnyak2, Catherine Liu1, Mark K. Louder1, Wei Shi1
10 ,Kwanyee Leung1, Eun Sung Yang1, Ande West3, Kendra L. Gully3, Nianshuang Wang8
11 , Daniel Wrapp8, Nicole A. Doria-Rose1, Guillaume Stewart-Jones2, Hamilton Bennett2
12 , Martha C.Nason9, Tracy J. Ruckwardt1, Jason S. McLellan8, Mark R. Denison6
, James D. Chappell6
13 , IanN. Moore5, Kaitlyn M. Morabito1, John R. Mascola1, Ralph S. Baric3,4, Andrea Carfi2
14 *, Barney S.Graham1
15 *
16